Skip to main content
Back to Investments

Marle

Status
Realised
Country
France
Strategy
Mid Cap
Entry
Jun-16
Exit
Dec-19
Fund
IK VII
Website

The leading European Contract Manufacturing Organisation of hip and knee orthopaedic implants

Established over 30 years ago as a family business, Marle has become a major company in the orthopaedic industry. The company provided specialised manufacturing services for the production of a wide range of hip, knee, shoulder, spine and extremities implants as well as orthopaedic instruments of the highest quality.

Covering the full scope of the manufacturing value chain and benefitting from remarkable R&D capabilities, Marle acted as a strategic partner to medical technology companies worldwide and delivered over 1 million products annually. At the time of exiting, Marle served orthopaedic implant OEMs across Europe, the US, Latin America, Russia, Japan, Korea and China.

The IK VII Fund acquired a majority stake from the Carlyle Group in June 2016. The investment was realised in December 2019, when IK sold to Dentressangle.

Our Value Creation Strategy

During our ownership, we worked alongside the management team to:

  • Leverage existing client base and further develop a one-stop-shop offering;
  • Expand activity worldwide and notably in the US either organically or via acquisitions; and
  • Pursue operational efficiency gains.